All sponsors

Taiho Oncology, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO70%

Delay Index: of 10 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +38.0 months). See all sponsors →

Open Taiho Oncology, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ASTX660
NCT02503423
P1/2Active, not recruitingSolid Tumors; Lymphoma2532022-10 (+51 mo)
Decitabine and Cedazuridine (ASTX727)
NCT04657081
P1/2Active, not recruitingAcute Myeloid Leukemia1012024-09-30 (+39 mo)
Futibatinib
NCT05945823
P2Active, not recruitingLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adenocarcinoma532026-10-01 (+21 mo)
FOENIX-CCA4
NCT05727176
P2RecruitingAdvanced Cholangiocarcinoma; FGFR2 Fusions1202026-12 (+18 mo)
futibatinib
NCT06506955
P2/3Active, not recruitingAdvanced/Metastatic Cancer152027-04 (+3 mo)
REZILIENT3
NCT05973773
P3Active, not recruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion Mutation2852027-05-27 (+5 mo)
Azacitidine
NCT04256317
P2/3RecruitingMyelodysplastic Syndromes; Acute Myeloid Leukemia3162027-11-01 (+55 mo)
ASTX727
NCT04093570
P2Enrolling by invitationAcute Myeloid Leukemia; Chronic Myelomonocytic Leukemia3322027-12-31 (+81 mo)
REZILIENT2
NCT05967689
P2RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations2202028-08-31 (+38 mo)
REZILIENT4
NCT07128199
P3RecruitingLung Cancer; Adjuvant3602029-10-01